Islet dysfunction in obese women with impaired glucose tolerance

Metabolism: Clinical and Experimental

Volumn 45, Issue 4, 1996, Pages 502-509

  Larsson, Hillevi ^a   Ahrén, Bo ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON; GLUCOSE; INSULIN;

ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; GLUCAGON BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; HUMAN; HYPERINSULINEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN RESPONSE; INSULIN SENSITIVITY; OBESITY; PRIORITY JOURNAL;

EID: 0029962983     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(96)90227-9     Document Type: Article

References (45)

1. Martin BC, Warram JH, Krolewski AS, et al: Role of glucose and insulin resistance in development of type 2 diabetes mellitus: Results of a 25-year follow-up study. Lancet 340:925-929, 1992
2. Lillioja S, Mott DM, Howard BV, et al: Impaired glucose tolerance as a disorder of insulin action. Longitudinal and cross-sectional studies in Pima Indians. N Engl J Med 318:1217-1225, 1988
3. Lundgren H, Bengtsson C, Blohmé G, et al: Fasting serum insulin concentration and early insulin response as risk determinants for developing diabetes. Diabetic Med 7:407-413, 1990
4. Haffner SM, Stern P, Watanabe RM, et al: Relationship of insulin clearance and secretion to insulin sensitivity in nondiabetic Mexican Americans. Eur J Clin Invest 22:147-153, 1992
5. Warram JH, Martin BC, Krolewski AS, et al: Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Intern Med 113:909-915, 1990
6. Felber J-P: From obesity to diabetes. Pathophysiological considerations. Int J Obes 16:937-952, 1992
7. O'Rahilly SP, Rudenski AS, Burnett MA, et al: Beta-cell dysfunction, rather than insulin insensitivity, is the primary defect in familial type 2 diabetes. Lancet 2:360-364, 1986
8. Mitrakou A, Kelley D, Mokan M, et al: Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 326:22-29, 1992
9. Kanatsuka A, Hideichi M, Sakurada M, et al: First-phase insulin response to glucose in nonobese or obese subjects with glucose intolerance: Analysis by C-peptide secretion rate. Metabolism 37:878-884, 1988
10. Larsson H, Berglund G, Ahrén B: Glucose modulation of insulin and glucagon secretion is altered in impaired glucose tolerance. J Clin Endocrinol Metab 80:1778-1782, 1995
11. Eriksson J, Franssila-Kallunki A, Ekstrand A, et al: Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. N Engl J Med 321:337-343, 1989
12. Pimenta W, Korytkowski M, Mitrakou A, et al: Pancreatic beta-cell dysfunction in normal glucose-tolerant individuals with a first-degree NIDDM relative. JAMA 273:1855-1861, 1995
13. Saad MF, Knowler WC, Pettitt DJ, et al: The natural history of impaired glucose tolerance in the Pima Indians. N Engl J Med 319:1500-1506, 1988
14. King H, Zimmet P, Raper LR, et al: The natural history of impaired glucose tolerance in the Micronesian population of Nauru: A six-year follow-up study. Diabetologia 26:39-43, 1984
15. Kadowaki T, Miyake Y, Hagura R, et al: Risk factors for worsening to diabetes in subjects with impaired glucose tolerance. Diabetologia 26:44-49, 1984
16. Keen H, Jarrett RJ, McCartney P: The ten-year follow-up of the Bedford survey (1962-1972): Glucose tolerance and diabetes. Diabetologia 22:73-78, 1982
17. Knowler WC, Pettitt DJ, Savage PJ, et al: Diabetes incidence in Pima Indians: Contributions of obesity and parental diabetes. Am J Epidemiol 113:144-156, 1981
18. Ohlson L-O, Larsson B, Svärdsudd K, et al: The influence of body fat distribution on the incidence of diabetes mellitus. 13.5 years of follow-up of the participants in the study of men born in 1913. Diabetes 34:1055-1058, 1985
19. Haffner SM, Stern MP, Mitchell BD, et al: Incidence of type II diabetes in Mexican Americans predicted by fasting insulin and glucose levels, obesity, and body-fat distribution. Diabetes 39:283-288, 1990
20. Olefsky M, Kolterman OG, Scarlet JA: Insulin action and resistance in obesity and non-insulin dependent type II diabetes mellitus. Am J Physiol 243:E15-E30, 1982
21. Zuniga-Guajardo S, Jimenez J, Angel A, et al: Effects of massive obesity on insulin sensitivity and insulin clearance and the metabolic response to insulin as assessed by the euglycemic clamp technique. Metabolism 35:278-282, 1986
22. Karam JH, Grodsky GM, Forsham PH: Excessive insulin response to glucose in obese subjects as measured by immunochemical assay. Diabetes 12:197-204, 1963
23. Perley M, Kipnis DM: Plasma insulin responses to glucose and tolbutamide of normal weight and obese diabetic and nondiabetic subjects. Diabetes 15:867-874, 1966
24. Polonsky KS, Given BD, Hirsch L, et al: Quantitative study of insulin secretion and clearance in normal and obese subjects. J Clin Invest 81:435-441, 1988
25. Kautzky-Wilier A, Pacini G, Ludvik B, et al: B-cell hypersecretion and not reduced hepatic insulin extraction is the main cause of hyperinsulinemia in obese nondiabetic subjects. Metabolism 41:1304-1312, 1992
26. DeFronzo RA, Tobin JD, Andres R: Glucose clamp technique: A method for quantifying insulin secretion and resistance. Am J Physiol 237:E214-223, 1979
27. Ward WK, Bolgiano DC, McKnight B, et al: Diminished β cell secretory capacity in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 74:1318-1328, 1984
28. Larsson H, Ahrén B, Lindgärde F, et al: Fasting blood glucose in determining prevalence of diabetes in a large, homogeneous population of Caucasian middle-aged women. J Intern Med 237:537-541, 1995
29. World Health Organization: Diabetes Mellitus: Report of a WHO Study Group. Technical Report Series no. 727. Geneva, Switzerland, World Health Organization, 1985
30. Cerasi E: Potentiation of insulin release by glucose in man. Acta Endocrinol 79:511-534, 1975
31. Grill V: Time and dose dependencies for priming effect of glucose on insulin secretion. Am J Physiol 240:E24-31, 1981
32. Halter JB, Graf RJ, Porte D Jr: Potentiation of insulin secretory response by plasma glucose levels in man: Evidence that hyperglycemia in diabetes compensates for impaired glucose potentiation. J Clin Endocrinol Metab 48:946-954, 1979
33. Porte D Jr: β cells in type II diabetes mellitus. Diabetes 40:166-180, 1991
34. Norusis MJ: SPSS for Windows: Base System User's Guide, Release 5.0. Chicago, IL, SPSS, 1992
35. Bergman RN, Phillips LS, Cobelli C: Physiologic evaluation of factors controlling glucose tolerance in man. J Clin Invest 68:1456-1467, 1981
36. Beard JC, Ward WK, Halter JB, et al: Relationship of islet function to insulin action in human obesity. J Clin Endocrinol Metab 65:59-64, 1987
37. 2+, cAMP, and phospholipid-derived messengers in coupling mechanisms of insulin secretion. Physiol Rev 67:1185-1248, 1987
38. Kautzky-Willer A, Pacini G, Niederle B, et al: Insulin secretion, insulin sensitivity, and hepatic insulin extraction in primary hyperparathyroidism before and after surgery. Clin Endocrinol 37:147-155, 1992
39. Balkan B, Dunning BE: Muscarining stimulation maintains in vivo insulin secretion in response to glucose after prolonged hyperglycemia. Am J Physiol 37:R475-479, 1995
40. Ahrén B, Taborsky Jr GJ: The mechanism of vagal nerve stimulation of glucagon and insulin secretion in the dog. Endocrinology 118:1551-1557, 1986
41. Lillioja S, Mott DM, Spraul M, et al: Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N Engl J Med 329:1988-1992, 1993
42. Unger RH, Grundy S: Hyperglycemia as an inducer as well as a consequence of impaired islet function and insulin resistance: Implications for the management of diabetes. Diabetologia 28:119-121, 1985
43. Efendic S, Luft R, Wajngot A: Aspects of the pathogenesis of type 2 diabetes. Endocr Rev 5:395-410, 1984
44. Hidaka H, Nagulesparan M, Klimes I, et al: Improvement of insulin secretion but not insulin resistance after short term control of plasma glucose in obese type II diabetes. J Clin Endocrinol Metab 54:217-222, 1982
45. DeFronzo RA, Bonadonna RC, Ferrannini E: Pathogenesis of NIDDM. A balanced overview. Diabetes Care 15:318-368, 1992